Terminated PHASE3 INTERVENTIONAL 2-arm NCT04300114

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Fluzoparib Monotherapy in Patients With gBRCA/PALB2 Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Metastatic Pancreatic Cancer

Interventions Fluzoparib Placebo

Updated 13 times since 2020 Last updated: Mar 27, 2024 Started: Aug 19, 2020 Primary completion: Feb 18, 2022 Completion: Feb 18, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor R \& D Strategy Adjustment

Other terminated trials from Jiangsu HengRui Medicine Co., Ltd.

More terminations from Jiangsu HengRui Medicine Co., Ltd.

Other Metastatic Pancreatic Cancer trials with similar outcome

Browse all Metastatic Pancreatic Cancer trials

A PHASE3 clinical study on Metastatic Pancreatic Cancer, this trial is terminated or withdrawn. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 13 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2024 — Jul 2024 [monthly]

Terminated PHASE3

Status: Unknown Status → Terminated
Feb 2023 — Apr 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Feb 2021 — Feb 2023 [monthly]

Recruiting PHASE3

▶ Show 8 earlier versions

Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Aug 2020 — Sep 2020 [monthly]

Not Yet Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE3
Jun 2020 — Jul 2020 [monthly]

Not Yet Recruiting PHASE3
May 2020 — Jun 2020 [monthly]

Not Yet Recruiting PHASE3
Apr 2020 — May 2020 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Harbin, China , Hefei, China , Jinan, China , Nanjing, China , Shanghai, China and 3 more locations